p53 and its mutants in tumor cell migration and invasion by Muller, Patricia A. J. et al.
The Rockefeller University Press
J. Cell Biol. Vol. 192 No. 2  209–218
www.jcb.org/cgi/doi/10.1083/jcb.201009059 JCB 209
JCB: Review
Correspondence to Jim C. Norman: j.norman@beatson.gla.ac.uk; or Patricia 
A.J. Muller: p.muller@beatson.gla.ac.uk
Abbreviations  used  in  this  paper:  EGFR,  EGF  receptor;  EMT,  epithelial– 
mesenchymal transition; GAP, GTPase-activating protein; GEF, guanine nucleotide 
exchange factor; RCP, Rab-coupling protein; ROCK, Rho-associated coiled-coil 
containing protein kinase.
Introduction
The p53 protein is probably the best known of all tumor sup­
pressors. In about half of all human cancers, p53 is either lost or 
mutated in a way that compromises its function. It is well estab­
lished that loss or inhibition of p53 prevents cellular senescence 
and apoptosis. And more recently, it has become clear that in 
situations where p53 function is compromised, other key pro­
cesses that impact tumor progression, such as cell migration and 
invasion, are altered. In various cancers, mutations have been 
found throughout Tp53, the gene that encodes p53. Many of 
these mutations give rise to mutant p53 proteins that are highly 
expressed. Recent data indicate that some of the most common 
mutant p53 proteins have, in addition to losing transcriptional 
function, acquired a gain of function: these mutants drive tumor 
cell migration and metastasis that is in part a result of their abil­
ity to interfere with another p53 family member, p63.
Loss of p53 is associated with an  
EMT-like phenotype
Normally, p53 levels are suppressed by the activity of the E3 ubiq­
uitin ligase MDM2 (mouse double minute 2; Haupt et al., 1997; 
Kubbutat et al., 1997). However, cellular stresses, such as DNA 
damage  or  oncogene  activation,  can  alleviate  this  suppres­
sion, leading to p53 stabilization. Thus, in tumors where p53 
expression is lost, the consequent inability of cells to engage 
apoptosis  or  senescence  after  stressful  insults  contributes  to   
tumor formation. However, in order to metastasize, tumor cells 
must disseminate from the primary tumor, invade the stroma to   
reach blood or lymph vessels, and then extravasate to colonize 
other tissues. In addition to affecting apoptosis and cellular   
senescence, p53 loss has recently been shown to influence cell 
motility in a way that can contribute to a tumor’s invasive and 
metastatic potential.
The Slug/Snail and Twist families of transcription factors 
are master regulators of key events in embryonic development, 
in  particular  the  epithelial–mesenchymal  transition  (EMT; 
Shiota et al., 2008). These transcriptional programs are char­
acterized by the loosening of cell–cell junctions and the acquisi­
tion of a more motile mesenchymal phenotype. More recently, 
Slug/Snail  and Twist  proteins  have  been  shown  to  down­ 
regulate molecules involved in stabilizing cell–cell junctions   
(such as E­cadherin), and to up­regulate components of the 
migratory machinery in order to become invasive (Bolós et al.,   
2003; Shih et al., 2005). Clearly, there is an important inter­
action between these master regulators of EMT and p53 (Fig. 1;   
Wang et al., 2009b). It is thought that in order to drive EMT, 
Twist opposes p53 function, indicating that p53 maintains a 
transcriptional program to prevent EMT and that loss of this 
suppression may contribute to the induction of an EMT­like 
phenotype in p53­null tumors (Shiota et al., 2008; Smit and 
Peeper,  2008). The  reciprocal  relationship  between  p53  and 
the execution of an EMT­like program is further exemplified 
by  recent  observations  that  expression  of  p53  can  promote 
MDM2­mediated degradation of Slug to enhance E­cadherin 
expression (Wang et al., 2009b). Consistent with the paradigm 
that carcinogenesis carries many characteristics of EMT, loss of 
E­cadherin is frequently observed in cancer, and this has been 
shown to be capable of driving metastasis in animal models 
(Derksen et al., 2006). In p53
+/ mice, most of the chemically 
induced papillomas with undetectable p53 expression display 
E­cadherin loss from the cell membrane, whereas papillomas 
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cell motility through the stroma. Expression of fibronectin and 
collagens, ECM proteins that are intrinsically associated with 
the acquisition and implementation of an elongated mesenchy­
mal migratory phenotype, are strongly increased after p53 loss 
(Guo and Zheng, 2004), potentially enhancing the interaction 
between cell and ECM to allow for cell motility.
It is clear that both the synthesis/deposition of ECM pro­
teins and their degradation by extracellular proteases are impor­
tant during the invasive process. Two recent studies have revealed 
a role for p53 in suppressing invadopodia that can trigger deg­
radation of components of the ECM and basal membrane to 
allow cells to access the stroma. In one of these studies, the 
actin­binding protein Caldesmon was identified as a transcrip­
tional target of p53. Caldesmon has been shown to inhibit po­
dosome formation after oncogenic transformation by activated 
forms of Src (Mukhopadhyay et al., 2009). Additionally, p53 
has been shown to regulate the microRNA (miRNA) 143 that 
might target various components of the invadopodia formation 
machinery and therefore inhibit podosome formation (Fig. 1; 
Quintavalle et al., 2010).
Loss of p53 activates Rho GTPases and 
their associated signaling pathways
Although p53’s ability to control expression of cytoskeletal and 
ECM proteins is undoubtedly important, it is also evident that 
signaling pathways modulating cell migration and the chemo­
tactic responses are influenced by p53. Most signals leading to 
altered cell migration and invasion converge on the Rho family 
of small GTPases. Members of this family, including Rac, cdc42, 
and Rho, control actin dynamics and are integral to cytoskeletal 
that retain wild­type p53 expression display normal E­cadherin 
expression (Cano et al., 1996). Increased Slug expression can 
also be identified in many p53­null tumors, and this correlates 
with loss of E­cadherin (Shih et al., 2005; Castro Alves et al., 
2007), which indicates that p53 loss can activate a more mesen­
chymal phenotype in human cancer. However, as not all tumors 
with p53 loss can be regarded as having undergone EMT, rela­
tively straightforward relationships between p53 expression and 
EMT regulators that have been identified in ex vivo and animal 
cancer models may not be considered as axioms with respect to 
the human disease.
p53 and cell interactions with the 
extracellular matrix
After their dissemination from tumors, metastatic cells acquire 
the capacity to actively migrate and invade through the stroma. 
Indeed, several studies have shown that deletion of p53 can 
change the morphology and polarity of fibroblasts, and that this 
allows  them  to  migrate  faster  in  scratch­wound  assays  and 
through  3D  matrices,  such  as  Matrigel  (Alexandrova  et  al., 
2000; Gadéa et al., 2002; Guo et al., 2003; Guo and Zheng, 
2004; Gadea et al., 2007. Moreover, studies linking loss of p53 
to increased cell motility are not restricted to fibroblasts; similar 
observations have been made in other cell types including kera­
tinocytes (Lefort et al., 2007), epithelial cancer lines (HCT116 
and H1299; Sablina et al., 2003; Xia and Land, 2007), and neu­
rons where increased growth cone motility has been associated 
with compromised p53 function (Qin et al., 2009). It has been 
known for some time that p53­regulated genes include compo­
nents of the adhesive machinery that are known to contribute to 
Figure 1.  p53 opposes EMT and cell migra-
tion to prevent metastasis. p53 plays a role 
in opposing EMT and cell migration. A hall-
mark of EMT is loss of E-cadherin, and p53 
can prevent this by inhibiting Slug or the ad-
hesion molecule EpCam expression. Further-
more, loss of p53 or decreased p53 activity   
after Twist expression can therefore drive EMT. 
p53 can also inhibit invasive migration. This can 
be mediated via increased expression of Cal-
desmon or miRNA-143 to oppose invadopodia   
formation.  By  transactivating  PTEN,  p53 
can reduce PIP3 (and thereby Rac) levels, re-
sulting in inhibition of mesenchymal/elongated 
motility. p53 can also inhibit amoeboid cell 
motility  by  preventing  activation  of  ROCK, 
either by inducing Notch or by promoting 
RhoE  (Rnd3)-mediated  inhibition  of  RhoA.   
E-CAD, E-cadherin.211 p53 and cell migration • Muller et al.
Sablina et al., 2003; Guo and Zheng, 2004; Roger et al., 2006; 
Gadea et al., 2007; Lefort et al., 2007; Xia and Land, 2007; Qin 
et al., 2009).
RhoA  acts  through  its  main  effector  Rho­associated 
coiled­coil containing protein kinase (ROCK) to promote con­
tractility, favoring rounded amoeboid migration as opposed to 
the elongated mode favored by Rac (Sahai and Marshall, 2003). 
It is not clear how amoeboid migration fits into an EMT para­
digm for tumor progression, but it certainly drives very rapid 
translocation of tumor cells through Matrigel and collagen gels, 
and intravital imaging indicates that this is how many tumor 
cells migrate in vivo (Pinner and Sahai, 2008). There is good 
consensus in the literature that loss of p53 leads to increased 
levels  of  GTP­bound,  active  RhoA  and  activated  ROCK,   
although the molecular details of how this occurs and conclu­
sions as to whether this represents the sole route from p53 loss 
to  altered  migration  varies  somewhat  between  studies  (Guo 
and Zheng, 2004; Gadea et al., 2007; Lefort et al., 2007; Qin   
et al., 2009). Indeed, Gadéa and coworkers have reported that 
the morphological changes occurring in p53
/ fibroblasts can 
be caused by activation of cdc42 (Gadéa et al., 2002) and/or 
RhoA/ROCK signaling (Gadea et al., 2007). However, given 
that the enhanced amoeboid migration of p53­null fibroblasts 
can  be  opposed  by  pharmacological  inhibition  of  ROCK 
changes  accompanying  tumor  cell  migration  and  invasion 
(Bishop and Hall, 2000; Heasman and Ridley, 2008). The up­
stream control of RhoGTPase activity is primarily mediated by 
molecules that influence their GTP loading, including RhoGAPs 
(Rho GTPase­activating proteins), which turn them off by in­
creasing GTP hydrolysis, and RhoGEFs (Rho guanine nucleo­
tide  exchange  factors)  that  activate  them  (Sanz­Moreno  and 
Marshall, 2009).
The balance between the activities of Rac and Rho has 
been well­established to influence the way in which tumor cells 
migrate (Sahai and Marshall, 2003; Sanz­Moreno and Marshall, 
2009). When Rac predominates, migration proceeds with the 
elongated morphology characteristic of tumor cells that have 
assumed a mesenchymal phenotype. Thus, given p53’s ability 
to suppress Slug and its attendant EMT­like program, it might 
be expected that p53­deficient cells would have increased   
levels of active Rac. Possible links between p53 and Rac can 
be garnered by considering findings that the PTEN gene, a lipid 
phosphatase that reduces levels of PIP3, leading to inhibition 
of PIP3­dependent GEFs for Rac and cdc42, can be transacti­
vated by p53 (Stambolic et al., 2001). However, although Rac 
and cdc42 activation was initially reported in p53­null cells, 
most subsequent studies have focused on increased activity of   
RhoA after loss of p53 (Table I and Fig. 1; Guo et al., 2003; 
Table I.  Loss of p53 function in cell migration
Primary  
transcriptional 
targets
Posttranscriptional  
effects 
Secondary transcrip-
tional targets
Downstream consequences References
Cellular level Tissue level
Unknown Slug ↑ (due to reduced 
mdm2-mediated  
degradation)
E-Cadherin ↓ Cell–cell  
junctions ↓
EMT-like  
phenotype
Cano et al., 1996; Shiota et al., 
2008; Wang et al., 2009b
EpCAM ↑ Unknown NA Cell–cell  
junctions ↓
EMT-like  
phenotype
Sankpal et al., 2009
RhoE ↓ ROCK ↑ NA Rho signaling ↑ Cell migration  
(2D and 3D) ↑
Ongusaha et al., 2006; Riento and 
Ridley, 2006
RhoE ↓ p190RhoGAP ↓ NA Rho signaling ↑ Cell migration  
(2D and 3D) ↑
Wennerberg et al., 2003
RhoE ↓ Syx RhoGEF ↑ NA Rho signaling ↑ Cell migration  
(2D and 3D) ↑
Goh and Manser, 2010
ROCK ↑ NA NA Rho signaling ↑ Cell migration  
(2D and 3D) ↑
Guo and Zheng, 2004; Gadea et al., 
2007; Lefort et al., 2007; Qin et 
al., 2009
Notch ↓ NA MRCK↑, ROCK↑ Rho signaling ↑ Cell migration  
(2D and 3D) ↑
Lefort et al., 2007
Fibronectin ↑ NA NA Rho signaling ↑ Cell migration  
(2D and 3D) ↑
Guo and Zheng, 2004
Collagens ↑ NA NA Rho signaling ↑ Cell migration  
(2D and 3D) ↑
Zhao et al., 2000
LASP1 ↑ NA NA Rho signaling ↑ Cell migration  
(2D and 3D) ↑
Wang et al., 2009a
PTEN ↓ Various Rac/ Cdc42↑ Rac and PKB/Akt 
signalling ↑
Cell migration  
(2D and 3D) ↑
Stambolic et al., 2001; Guo et al., 
2003; Guo and Zheng, 2004; 
Gadea et al., 2007
MMP2 ↑ NA NA NA ECM degradation ↑ Delassus et al., 2010
miRNA-143 ↑ Various NA Invadopodia ↑ ECM degradation ↑ Quintavalle et al., 2010
Caldesmon ↑ NA NA Invadopodia ↑ ECM degradation ↑ Mukhopadhyay et al., 2009
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will focus on the gain of function of mutant p53 in driving   
tumor cell migration.
Gain of function of mutant p53 in driving cell migra­
tion has been shown across different contexts, including cell 
movement on 2D surfaces, invasive­type migration through 3D   
matrices (such as Matrigel), and metastasis of mutant p53 cells 
implanted as xenografts (Dhar et al., 2008; Junk et al., 2008; 
Adorno et al., 2009; Muller et al., 2009). To gain insight into 
how this gain of function is achieved by mutant p53, several 
groups have addressed the possibility that mutant p53 expression 
changes the transcriptional profile of cells in a p53­null back­
ground.  Interestingly,  many  mutant  p53­regulated  genes  are 
ones that would be expected to influence cell migration either 
directly or indirectly (Table II). Indeed, mutant p53s can act 
via Slug or Twist to induce partial EMT­like transitions that   
are reflected in their ability to suppress E­cadherin synthesis 
(Wang et al., 2009b; Kogan­Sakin et al., 2010), or this can be me­
diated via suppression of the anti­invasive gene CCN­5/WISP2 
(Dhar et al., 2008). Many cancer cells invade the stroma using   
an amoeboid migratory mode that is promoted by increased 
RhoA/ROCK signaling, and several studies have found compo­
nents of this pathway to be transcriptionally regulated by mu­
tant p53s. Indeed, recent studies indicate that both the guanine 
nucleotide dissociation inhibitor (RhoGDI; Bossi et al., 2008) 
and an exchange factor for RhoA (Rho GEF­H1; Mizuarai et al., 
2006) are up­regulated by mutant p53s, and more work will be 
needed to determine how the combination of these changes im­
pacts on GTP­RhoA levels and the acquisition of amoeboid­
type migration in cancer.
Mechanisms of mutant p53’s gain  
of function
Overall,  two  main  mechanisms  that  could  underlie  mutant 
p53’s gain of function have been intensively studied by many 
groups. First, mutant p53 has been proposed to be a transcrip­
tion factor in its own right. Even though the majority of mu­
tations within p53 occur in the DNA binding domain, mutant 
p53s might still influence promoter activity via the N­terminal 
transactivation domain, and, as the expression of mutant p53 
is often very high in many cancers, this may be sufficient to 
drive the expression of its own set of target genes (Weisz et al., 
2004; Zalcenstein et al., 2006). Indeed, the ability of mutant 
p53 to oppose apoptosis is ablated by removal of its N­terminal   
transactivation domain (Lin et al., 1995; Matas et al., 2001). 
However, mutant p53 is also known to operate by interfering 
with and/or modifying the function of other proteins. For in­
stance, mutant p53 can interact with Mre11 to prevent ataxia 
telangiectasia  mutated  (ATM)­dependent  DNA  repair  (Song   
et al., 2007; Liu et al., 2010). Importantly, p53 is also known 
to impose upon the function of other transcription factors, in­
cluding the well­studied p53 family members, p63 and p73, 
that share a homologous transactivation domain, a DNA bind­
ing domain, and an oligomerization domain. Indeed, both cell­
based assays (Di Como et al., 1999; Strano et al., 2000, 2002) 
and knock­in mice expressing mutant forms of p53 support a 
mechanism by which mutant p53s interact with p63 and p73, 
and negatively regulate their function (Lang et al., 2004; Li and 
(Gadea  et al., 2007), it is likely that RhoA is an important   
effector of p53 with regard to this type of tumor cell migration. 
It is not clear how p53 loss leads to ROCK activation, but recent 
studies have suggested two plausible mechanisms by which this 
might occur. In keratinocytes, the expression of ROCK is re­
pressed by p53 via down­regulation of Notch1 (Lefort et al., 
2007). Additionally, the atypical Rho protein RhoE (or Rnd3) 
is a p53 target gene that opposes activation of RhoA (Ongusaha   
et al., 2006). Indeed, this can be mediated via RhoE’s ability   
both to inhibit Syx (a GEF that activates RhoA; Goh and   
Manser, 2010) and to activate p190­RhoGAP (a key RhoA inacti­
vator; Wennerberg et al., 2003). Furthermore, loss of p53 has 
been shown to reduce phosphorylation of p190­RhoGAP on 
Tyr
1105 in Ras­transformed cells (Xia and Land, 2007) to oppose 
RhoGAP activity (Fig. 1). These observations collectively pro­
vide evidence for signaling mechanisms through which p53 loss 
can drive increased activity of the RhoA/ROCK axis to promote 
cell motility and invasion during tumor progression.
Mutant p53 proteins drive an aggressive 
cancer phenotype by gain of function
Although p53 knockout mice are highly tumor prone, these le­
sions do not metastasize frequently, nor do they generally dis­
play invasive pathology (Attardi and Jacks, 1999). This suggests 
that p53 loss is not, in itself, sufficient to drive invasive migra­
tion in vivo. However, in many human tumors, p53 expression 
is not lost, but the gene acquires point mutations that disrupt 
the ability of the p53 protein to bind to DNA. Two p53 mutants 
that are commonly found in human cancer and that have been 
extensively used to study p53’s role in cell migration are R273H 
(R270H in mice), which directly compromises DNA binding, 
and R175H (R172H in mice), which causes a global confor­
mational distortion of p53 (Cho et al., 1994). These mutations 
inhibit p53’s ability to act as a transcription factor, account­
ing for their reduced ability to function as tumor suppressors. 
Moreover, these mutant p53 proteins are often expressed at very 
high levels in cancer cells, and a growing body of evidence now 
supports additional gain­of­function roles for mutant p53s in 
the context of tumorigenesis, cancer invasion, and metastasis 
(Oren and Rotter, 2010) Indeed, introduction of mutant p53s 
(R172H or R270H) leads to a marked increase in the incidence 
of highly metastatic carcinomas in various mouse models (Liu 
et al., 2000; Lang et al., 2004; Olive et al., 2004; Heinlein et al., 
2008; Doyle et al., 2010; Morton et al., 2010).
Mutant p53 proteins and cell migration
Wild­type p53 can be inhibited in trans by p53 mutants under 
conditions of high mutant p53 expression, so it is only possible 
to assign bona fide gain of function to mutant p53s when they 
are expressed in a p53­null background. Using both cell­based 
approaches and knock­in mice, mutant p53s have been shown to 
acquire new functions in processes such as proliferation, resis­
tance to apoptosis, genomic instability, somatic cell reprogram­
ming, and cell migration and invasion (Li et al., 1998; Gurtner 
et al., 2010; Liu et al., 2010; Oren and Rotter, 2010; Sarig et al., 
2010; Stambolsky et al., 2010). Although many of these pro­
cesses will likely contribute to tumor aggressiveness, here we 213 p53 and cell migration • Muller et al.
Although mutations in p63 have rarely been found, loss of p63 
is seen in a range of tumor types correlating closely with the in­
vasiveness of these cancers (Park et al., 2000; Urist et al., 2002; 
Wang et al., 2002; Koga et al., 2003; Chen et al., 2004). With 
regard to invasiveness, p63 loss may be restricted to the TAp63 
isoform, reinforcing the view that TAp63 functions as a sup­
pressor of metastasis (Park et al., 2000; Chen et al., 2004).   
Furthermore, p63
+/ mice can spontaneously develop solid ma­
lignant lesions, which primarily include squamous cell and his­
tiocytic sarcomas that are highly metastatic (Flores et al., 2005). 
Interestingly, most tumor formation in p63
+/ mice is accompa­
nied by loss of the remaining p63 allele, and in tumors where 
this does not occur, it is primarily the Np63 isoform that re­
mains (Flores et al., 2005). More recent data obtained in TAp63­
specific knockout mice indicate that TAp63 is required to drive 
Ras­dependent senescence and that its loss results in rapid p53­
independent tumorigenesis, which further supports a role for 
TAp63 in tumor suppression (Guo et al., 2009). At the cellular 
level, it is clear that siRNA knockdown of p63 increases inva­
sive migration of H1299 nonsmall lung cell carcinoma cells 
(Adorno et al., 2009; Muller et al., 2009). H1299 cells predomi­
nantly express TAp63 (Muller et al., 2009), and expression of 
mutant p53 recapitulates the effects of TAp63 loss, which indi­
cates that mutant p53’s gain of function may operate by specifi­
cally inhibiting the TA isoform of p63 (Adorno et al., 2009; 
Muller et al., 2009). These data also further demonstrate that the 
TAp63 isoform functions as an inhibitor of invasion.
So how do mutant p53s inhibit p63? Physical interactions 
between mutant p53s and p63 that directly impair its tran­
scriptional functions have been described previously (Gaiddon 
et al., 2001; Strano et al., 2002; Li and Prives, 2007). How­
ever, the relationship between mutant p53’s ability to bind p63 
and its capacity to functionally inhibit it to promote invasion is 
Prives, 2007). For example, knockdown of either p63 or p73   
is as effective as expression of a mutant p53 in increasing the 
colony­forming potential of fibroblasts from p53
/ mice.   
Furthermore, knockdown of p63 or p73 does not further increase 
colony formation in cells expressing a mutant p53, which indi­
cates the likelihood that these three p53 family members may be 
acting on similar pathways to tumorigenesis (Lang et al., 2004). 
Moreover, removal of the transactivation domain from mutant 
p53s does not interfere with its invasive capabilities, suggest­
ing that gain of function in driving invasion is predominantly 
mediated by inhibition of p63 and/or p73 (Adorno et al., 2009; 
Muller et al., 2009).
p63 is an effector of mutant p53
p63 expression is driven by two alternative promoters, resulting 
in a full­length TA isoform or an N­terminally truncated N 
form that lacks the transactivation domain. Furthermore, Np63 
and TAp63 transcripts can be spliced to yield , , or  variants 
with alternative C termini. Not only do these isoforms and vari­
ants have different expression patterns according to cell type 
and differentiation status, they have been reported to possess 
different and sometimes opposing functions, which complicates 
the understanding of p63 function. cDNA microarray data indi­
cates that overexpression of Np63 or TAp63 results in largely 
nonoverlapping gene expression profiles, which suggests that 
these two p63 isoforms could have different target genes (Wu   
et al., 2003; Carroll et al., 2006). However, observations that 
Np63 opposes TAp63 as an inducer of apoptosis suggest that 
it might exert inhibition over the TA isoform, nominate TAp63 
as a tumor suppressor, and nominate Np63 to be a tumor pro­
moter (Candi et al., 2007).
To be a suppressor of tumor growth and metastasis, one 
might expect p63 to be mutated or lost in human cancers.   
Table II.  Mutant p53-regulated events that impact cell migration
“Direct” target 
genes
Via p63 inhibition Secondary  
machinery
Downstream consequences References
Cellular level Tissue level
RhoGEF-H1 ↑ Unknown NA Integrin and Rho GTPase signalling ↑ Cell growth and  
migration ↑
Mizuarai et al., 2006
RhoGDI ↑ Unknown NA Integrin and Rho GTPase signalling ↑ Cell growth and  
migration ↑
Bossi et al., 2008
IGF1R ↑ Unknown NA Integrin and Rho GTPase signalling ↑ Cell growth and  
migration ↑
Bossi et al., 2008
Paxillin- ↑ Unknown NA Integrin and Rho GTPase signalling ↑ Cell growth and  
migration ↑
Bossi et al., 2008
WISP2/CCN5 ↓ Unknown NA Integrin and Rho GTPase signalling ↑ Cell growth and  
migration ↑
Dhar et al., 2008
Sharp-1 ↓ Yes NA Unknown Tumor cell migration  
and invasion ↑
Adorno et al., 2009
Cyclin G2 ↓ Yes NA Unknown Tumor cell migration  
and invasion ↑
Adorno et al., 2009
Unknown Yes RCP-dependent 
trafficking
51 integrin/EGFR recycling Tumor cell migration  
and invasion ↑
Muller et al., 2009
Twist ↑ Unknown NA Unknown EMT Kogan-Sakin et al., 
2010
Selected list of genes/proteins that affect EMT, cell migration, invasion, and metastasis that are regulated by mutant p53 in a gain-of-function manner. p53 status, 
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are likely other members of the mutant p53–p63 complex that 
influence the way in which the two proteins associate. Adorno 
et al. (2009) have shown a role for TGF­ signaling in promot­
ing the ability of mutant p53 to bind to and inhibit p63. These 
investigators demonstrated that SMAD2 phosphorylated down­
stream of TGF­ can serve as a platform for assembly of the 
mutant p53–p63 complex. This pathway illustrates an important 
mechanism by which TGF­ can control invasion. However, the 
relationships between TGF­ signaling and mutant p53 are not 
not straightforward. Although both the R175H and R273H   
mutants of p53 are equally capable of inhibiting TAp63 and 
promoting invasion, p53R175H binds more tightly to TAp63 
in coimmunoprecipitation experiments (Gaiddon et al., 2001; 
Strano  et  al.,  2002;  Li  and  Prives,  2007).  Furthermore,  a   
C­terminally truncated mutant p53 does not drive invasion, but 
still interacts with TAp63, which suggests that mutant p53’s 
inhibition of p63 is not dictated exclusively by the capacity of 
the two proteins to associate with one another. Moreover, there 
Figure 2.  Mutant p53 regulates cell migration and invasion by inhibiting p63. (A) Upon TGF- induction, SMAD2 is phosphorylated and promotes binding 
of mutant p53 to p63, alleviating p63-mediated suppression of Sharp-1 and Cyclin G2 to allow for cell migration and invasion. (B) p63 inhibits activation 
of RCP (through transcriptional targets that are currently unknown) to prevent 51 integrin and EGFR recycling to the plasma membrane. Upon expression 
of mutant p53, p63 activity is suppressed, resulting in enhanced RCP-driven recycling of 51 integrin and EGFR. This activates Rho and PKB/Akt to 
promote cell migration and invasion.215 p53 and cell migration • Muller et al.
to identify genes that may regulate components of the miRNA 
processing complex, an RNase III endonuclease, Dicer, was 
identified as a possible target of TAp63 (Boominathan, 2010). 
Conformation that Dicer is indeed a target gene of TAp63 was 
recently provided by an elegant study showing that TAp63 regu­
lates Dicer to prevent metastasis (Su et al., 2010). p63­null mice 
die soon after birth because of severe skin defects. To parallel 
this, the epidermis­specific knockout of Dicer leads to impaired 
development of hair follicles (Andl et al., 2006). Down­regulation 
of miRNA processing is known to occur in a range of cancers 
(Lu et al., 2005; Kumar et al., 2009), and reduced levels of en­
zymes such as Dicer correlate with a poor prognosis (Grelier   
et al., 2009). Moreover, it has recently been shown that reduced 
levels of Dicer can promote tumorigenesis and invasion (Kumar   
et al., 2009; Han et al., 2010; Lambertz et al., 2010; Martello   
et al., 2010; Su et al., 2010). Furthermore, decreased Dicer   
levels correlate with increased activation of PKB/Akt, which 
suggests that it might act on the same pathway to induce inva­
sion as mutant p53 and p63 (Han et al., 2010). Hopefully, future 
work will resolve the molecular details of the connection between 
p63 suppression, miRNA processing, and invasion. In particu­
lar, it will be interesting to determine whether components of 
the trafficking machinery that transport 51 integrin from re­
cycling endosomes to the cell surface represent key targets of 
p63­regulated miRNAs.
Mutant p53, p63, and growth factor 
receptor trafficking
In addition to controlling recycling of 51 integrin, RCP can 
physically link the integrin to the EGF receptor (EGFR), thus 
mediating co­trafficking of these two important regulators of 
cell migration (Caswell et al., 2008). Moreover, because this 
process leads to increased return of internalized EGFR1 to the 
plasma membrane (thus diverting it from the route to lyso­
somal degradation), it also enhances signaling downstream of 
EGFR1 (Caswell et al., 2008). Consistent with this, mutant p53­ 
expressing  cells  have  enhanced  levels  of  active  PKB/Akt   
(Fig. 2 B; Dong et al., 2009; Muller et al., 2009), and the mutant 
p53 status of human and mouse cancers correlates with the degree 
of PKB/Akt activation (Muller et al., 2009; Blanco­Aparicio 
et al., 2010). PKB/Akt is an important prosurvival kinase that 
more recently has been established to play a key role in pro­
moting cell migration during the invasive program. This indi­
cates the likelihood that mutant p53­driven recycling conveys 
its signals to the cell’s invasive machinery, at least in part, via 
PKB/Akt. Another member of the EGFR family, ErbB2, can 
heterodimerize with EGFR1, and is known to cooperate with 
mutant p53 to increase tumorigenesis in mice (Li et al., 1997). 
Furthermore, in breast cancers, mutant p53 status in combina­
tion with high ErbB2 expression is associated with a very poor 
prognosis (Rahko et al., 2003). Alternative trafficking routes for 
EGFR1/ErbB2 heterodimers are thought to influence EGF sig­
naling in cancer (Lenferink et al., 1998), and the possibility that 
the 51 integrin–RCP complex recruits and controls recycling 
of EGFR1/ErbB2 heterodimers and other prometastatic recep­
tors with known connections to mutant p53, such as IGF1R and 
c­Met, should be considered.
straightforward, and it would seem that TGF­ signaling is not 
always required for mutant p53 to function (Kalo et al., 2007; 
Muller et al., 2009). It is well known that TGF­ signaling 
has many complex and opposing roles in cancer progression   
(Jakowlew, 2006), and the involvement of phospho­SMAD2 in 
the regulation of p63 and cell migration by mutant p53 sheds 
some interesting light on at least some of the functions of   
TGF­ in cancer progression.
Downstream of p63 to drive invasion  
and metastasis
Transcriptome studies indicate that knockdown of p63 increases 
expression of known mediators of motility, invasion, and metas­
tasis (Barbieri et al., 2006; Carroll et al., 2006; Gu et al., 2008). 
To identify factors downstream of p63 that were responsible for 
invasion, Adorno et al. (2009) investigated genes that were co­
regulated by mutant p53 and TGF­, and identified Sharp­1 and 
Cyclin G2 as important targets. Suppression of either Sharp­1 
or Cyclin G2 mimicked mutant p53’s capacity to drive cell   
migration, and low expression of Sharp­1 and Cyclin G2 was 
associated with poor prognosis and recurrence in breast cancer. 
Collectively, these data indicate that Sharp­1 and Cyclin G2 are 
targets of p63 in regard to its ability to suppress tumor cell   
migration and metastasis (Fig. 2 A; Adorno et al., 2009).
But what are the components of the cell’s intracellular sig­
naling network and/or migratory machinery that respond to p63 
inhibition to engage tumor cell migration and invasion? It is 
now accepted that the cell’s main receptor for fibronectin, 51 
integrin, is a key contributor to metastatic migration of cancer 
cells. Indeed, Muller et al. (2009) showed that the mutant p53­
driven (and p63­inhibitable) component of tumor cell migration 
can depend on 51 integrin function and the presence of its   
ligand, fibronectin (Muller et al., 2009). The way in which inte­
grins are internalized into endosomal compartments and returned 
(or recycled) to the plasma membrane influences their function, 
particularly with regard to their communication with Rho­GTPases 
and their ability to influence the recycling of other receptors 
such as EGFR1 or VEGFR2 (Caswell et al., 2009). The Rab11 
effector protein Rab­coupling protein (RCP) associates with 
51 integrin and plays an important role in guiding integrin 
transport from recycling endosomes to the plasma membrane to 
promote movement of tumor cells in fibronectin­rich 3D micro­
environments (Caswell et al., 2008). Moreover, the importance of 
RCP in cancer progression is further illustrated by the finding that 
it is frequently overexpressed in human breast cancers (Zhang   
et al., 2009). It is now clear that the association of RCP with 51 
integrin is inhibited by transcriptionally active TAp63. This in­
hibition is relieved after expression of mutant p53s, allowing 
RCP to bind to internalized 51 integrin and rapidly transport 
it to the plasma membrane, thus driving tumor cell migration and 
invasion (Fig. 2 B; Muller et al., 2009).
Although  RCP­dependent  integrin  recycling  is  a  key   
effector pathway downstream of p63, the transcriptional targets 
of p63 that regulate RCP’s recruitment to 51 integrin are un­
known. It is interesting to speculate how this may be achieved, 
and there are signs that miRNAs and the machinery that pro­
cesses them may be involved. In a computational genomic analysis JCB • VOLUME 192 • NUMBER 2 • 2011   216
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Conclusions
By comparison with p53 loss, expression of mutant p53s is   
associated with more invasive and metastatic cancers, which 
suggests that these mutants not only lose the ability to function 
as tumor suppressors, but that they also gain prometastatic func­
tions, some of which are related to increased cell migration and 
invasion. In general, it seems that loss of p53 is important in the 
loosening of cell–cell junctions and the loss of epithelial integ­
rity, which would be expected to contribute to dissemination of 
cells from solid tumors. However, most in vivo work indicates 
that this event in itself is insufficient to generate invasive or 
metastatic tumors. Mutant p53s, however, are very potent in­
ducers of the metastatic phenotype. This owes, at least in part, 
to their ability to act via p63 to drive invasive­type migration. 
The contribution of TGF­ signaling and the trafficking of inte­
grins and growth factor receptors to mutant p53­driven invasion 
suggests some interesting new candidates for antimetastatic drug 
development. However, many questions remain as to how the ele­
ments of this pro­invasive program are connected to one another. 
In particular, we anticipate that the link between p63 and the 
cell’s migratory and trafficking machinery will provide fertile 
ground for those interested in targeting the metastatic process.
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